A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic

Abstract

The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced owing to emerging variants of concern 1,2 . Development of host-directed therapeutics and prophylactics could limit such resistance and offer urgently needed protection against variants of concern 3,4 . Attractive pharmacological targets to impede viral entry include type-II transmembrane serine proteases (TTSPs) such as TMPRSS2; these proteases cleave the viral spike protein to expose the fusion peptide for cell entry, and thus have an essential role in the virus lifecycle 5,6 . Here we identify and characterize a small-molecule compound, N-0385, which exhibits low nanomolar potency and a selectivity index of higher than 10 6 in inhibiting SARS-CoV-2 infection in human lung cells and in donor-derived colonoids 7 . In Calu-3 cells it inhibits the entry of the SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta). Notably, in the K18-human ACE2 transgenic mouse model of severe COVID-19, we found that N-0385 affords a high level of prophylactic and therapeutic benefit after multiple administrations or even after a single administration. Together, our findings show that TTSP-mediated proteolytic maturation of the spike protein is critical for SARS-CoV-2 infection in vivo, and suggest that N-0385 provides an effective early treatment option against COVID-19 and emerging SARS-CoV-2 variants of concern.

References 67

1. 1.

   Planas D, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021;602:671-675.

   Not in our library10.1038/s41586-021-04389-z

2. 2.

   Tao K, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 2021;22:757-773.

   Not in our library10.1038/s41576-021-00408-x

3. 3.
   Cell entry mechanisms of SARS-CoV-2 · 2020

   No notice
4. 4.

   Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.

   Not in our library10.1016/j.cell.2020.02.052

5. 5.

   Wong JP, Damania B. SARS-CoV-2 dependence on host pathways. Science. 2021;371:884-885.

   Not in our library10.1126/science.abg6837

6. 6.

   Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3-20.

   Not in our library10.1038/s41580-021-00418-x

7. 7.

   Rees WD, et al. Enteroids derived from inflammatory bowel disease patients display dysregulated endoplasmic reticulum stress pathways, leading to differential inflammatory responses and dendritic cell maturation. J. Crohns Colitis. 2020;14:948-961.

   Not in our library10.1093/ecco-jcc/jjz194

8. 8.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

   No notice
9. 9.

   COVID-19 Dashboard. Center for Systems Science and Engineering (CSSE) at Johns Hopkins Universityhttps://coronavirus.jhu.edu/map.html.

   Not in our library10.1016/s1473-3099(22)00434-0

10. 10.

    Callaway E. Beyond Omicron: what’s next for COVID’s viral evolution. Nature. 2021;600:204-207.

    Not in our library10.1038/d41586-021-03619-8

11. 11.

    Plante JA, et al. The variant gambit: COVID-19’s next move. Cell Host Microbe. 2021;29:508-515.

    Not in our library10.1016/j.chom.2021.02.020

12. 12.

    Sievers BL, et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci. Transl. Med. 2022;14:eabn7842.

    Not in our library10.1126/scitranslmed.abn7842

13. 13.

    Chitalia VC, Munawar AH. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. J. Transl. Med. 2020;18:390.

    Not in our library10.1186/s12967-020-02476-9

14. 14.
    SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development · 2021

    No notice
15. 15.
    Mechanism of SARS-CoV-2 polymerase stalling by remdesivir · 2021

    No notice
16. 16.

    Beigel JH, et al. Remdesivir for the treatment of Covid-19—final report. N. Engl. J. Med. 2020;383:1813-1826.

    Not in our library10.1056/nejmoa2007764

17. 17.

    Owen DR, et al. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586-1593.

    Not in our library10.1126/science.abl4784

18. 18.

    Wahl A, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451-457.

    Not in our library10.1038/s41586-021-03312-w

19. 19.

    Gunst JD, et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. eClinicalMedicine. 2021;35:100849.

    Not in our library10.1016/j.eclinm.2021.100849

20. 20.

    Beumer J, et al. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. Nat. Commun. 2021;12:5498.

    Not in our library10.1038/s41467-021-25729-7

21. 21.

    Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell. 2020;78:779-784.

    Not in our library10.1016/j.molcel.2020.04.022

22. 22.

    Tang T, et al. Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: potential role of proteases beyond furin. ACS Infect. Dis. 2021;7:264-272.

    Not in our library10.1021/acsinfecdis.0c00701

23. 23.

    Hoffmann M, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. eBioMedicine. 2021;65:103255.

    Not in our library10.1016/j.ebiom.2021.103255

24. 24.
    Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection · 2020

    No notice
25. 25.
    Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A · 2021

    No notice
26. 26.

    Dampalla, C. S. et al. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. Proc. Natl Acad. Sci. USA 118, e2101555118 (2021).

    Not in our library10.1073/pnas.2101555118

27. 27.

    Colombo É, et al. Design and synthesis of potent, selective inhibitors of matriptase. ACS Med. Chem. Lett. 2012;3:530-534.

    Not in our library10.1021/ml3000534

28. 28.

    Beaulieu A, et al. Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium. J. Virol. 2013;87:4237-4251.

    Not in our library10.1128/jvi.03005-12

29. 29.

    St-Georges C, et al. Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids. Eur. J. Med. Chem. 2017;129:110-123.

    Not in our library10.1016/j.ejmech.2017.02.006

30. 30.

    Murza A, et al. Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract–a review of patent literature. Expert Opin. Ther. Pat. 2020;30:807-824.

    Not in our library10.1080/13543776.2020.1817390

31. 31.

    Shrimp JH, et al. An enzymatic TMPRSS2 assay for assessment of clinical candidates and discovery of inhibitors as potential treatment of COVID-19. ACS Pharmacol. Transl. Sci. 2020;3:997-1007.

    Not in our library10.1021/acsptsci.0c00106

32. 32.

    Béliveau F, et al. Discovery and development of TMPRSS6 inhibitors modulating hepcidin levels in human hepatocytes. Cell Chem. Biol. 2019;26:1559-1572.

    Not in our library10.1016/j.chembiol.2019.09.004

33. 33.

    Long RKM, et al. Super resolution microscopy and deep learning identify Zika virus reorganization of the endoplasmic reticulum. Sci. Rep. 2020;10:20937.

    Not in our library10.1038/s41598-020-77170-3

34. 34.

    Staab JF, Lemme-Dumit JM, Latanich R, Pasetti MF, Zachos NC. Co-culture system of human enteroids/colonoids with innate immune cells. Curr. Protoc. Immunol. 2020;131:e113.

    Not in our library10.1002/cpim.113

35. 35.
    SARS-CoV-2 productively infects human gut enterocytes · 2020

    No notice
36. 36.

    Winkler ES, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 2020;21:1327-1335.

    Not in our library10.1038/s41590-020-0778-2

37. 37.

    McCray PB, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 2007;81:813-821.

    Not in our library10.1128/jvi.02012-06

38. 38.

    Johansen MD, et al. Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunol. 2020;13:877-891.

    Not in our library10.1038/s41385-020-00340-z

39. 39.
    Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model · 2021

    Not checked
40. 40.

    Laporte M, Naesens L. Airway proteases: an emerging drug target for influenza and other respiratory virus infections. Curr. Opin. Virol. 2017;24:16-24.

    Not in our library10.1016/j.coviro.2017.03.018

Cited by papers we hold 1

• An intranasal ASO therapeutic targeting SARS-CoV-2 · 2022
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.